Mabwell (Shanghai) Bioscience (SHA:688062) received approval from China's National Medical Products Administration for the clinical trial of 9MW5211 injection, according to a Saturday disclosure on the Shanghai bourse.
The Chinese pharmaceutical company's shares dropped 7% during Monday's afternoon trade.
The drug will be tested as a treatment for primary biliary cholangitis. It is also under study for inflammatory bowel disease, multiple sclerosis, type 1 diabetes and vitiligo.